R&D
Novartis’s Oral MS Pill Beats a Standard Drug in Two Big Trials
Remibrutinib, a BTK inhibitor, cut relapses and brain lesions versus a widely used oral MS medicine — and appeared to avoid the liver problems that have dogged its drug class.